Strategic Development Advisor

Alejandra Mørk, PhD and MSc Pharm, has more than 30 years of experience in drug development and life cycle management. In 2008, Alejandra acquired KLIFO to build an international end to end drug development consultancy. From 2008 to 2023 she was CEO of the company. Prior to acquiring KLIFO, Alejandra spent 18 years at Nycomed Pharma in various leadership positions in Project Management, Clinical Development and Regulatory Affairs and was overall responsible for Drug Development.

Member of the Board of Directors at the Danish industry association Danish Bio and at Scandion Oncology.